Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by high levels of nonesterified fatty acids (NEFA), inflammation, and hepatic steatosis. Inflammation plays a crucial role in the development of fatty liver. Resveratrol (RSV) supplement could improve inflammatory response and hepatic steatosis, whereas the underlying mechanism was not well understood. In this study, mice fed with high-fat diet (HFD) exhibited severe hepatic injury and high blood concentrations of the inflammatory cytokines TNF-α, IL-6, and IL-1β. Hepatic NF-κB inflammatory pathway was over-induced in HFD mice. In vitro, NEFA treatment further increased NF-κB pathway activation in mice hepatocytes, which then promoted the synthesis of inflammatory cytokines. Interestingly, RSV treatment significantly inhibited overactivation of NF-κB pathway and improved hepatic steatosis. Furthermore, RSV further increased the AMP-activated protein kinaseα (AMPKα) phosphorylation and sirtuin1 (SIRT1) protein levels to inhibit overactivation of NF-κB pathway induced by HFD or high levels of NEFA. AMPKα or SIRT1 inhibition significantly decreased the improvement effect of RSV on the NF-κB pathway induced by high levels of NEFA. Taken together, these findings indicate that RSV supplement decreases the inflammatory level and improves hepatic steatosis through activating AMPKα-SIRT1 pathway. Therefore, these data suggested an important clinical application of RSV in preventing NAFLD in humans.
Similar content being viewed by others
References
Mendez-Sanchez N, Arrese M, Zamora-Valdes D, Uribe M (2007) Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int. 27:423–433
Su YM, Lv GR, Xie JX, Wang ZH, Lin HT (2013) Maternal hypoxia increases the susceptibility of adult rat male offspring to HFD-induced non-alcoholic fatty liver disease. Endocrinology 154:4377–4387
Reddy JK, Rao MS (2006) Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290:852–858
Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52:1836–1846
Baker RG, Hayden MS, Ghosh S (2011) NF-κB, inflammation, metabolic disease. Cell Metab. 13:11–22
Gruben N, Shiri-Sverdlov R, Koonen DPY, Hofker MH (2014) Nonalcoholic fatty liver disease: a main driver of insulin resistance or a dangerous liaison? BBA Mol Basis Dis. 1842:2329–2343
Baffy G (2009) Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 51:212–223
Miura K, Seki E, Ohnishi H, Brenner DA (2010) Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract. Article ID: 362847
Poulsen MM, Larsen JØ, Hamilton-Dutoit S, Clasen BF, Jessen N, Paulsen SK (2012) Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a HFD. Nutr Res. 32:701–708
Li X, Huang W, Gu J, Du X, Lei L, Yuan X (2015) SREBP-1c overactivates ROS-mediated hepatic NF-κB inflammatory pathway in dairy cows with fatty liver. Cell Signal 27:2099–2109
Shi X, Li D, Deng Q, Li Y, Sun G, Yuan X (2015) NEFAs activate the oxidative stress-mediated NF-kB signaling pathway to induce inflammatory response in calf hepatocytes. J Steroid Biochem Mol Biol 145:103–112
Shakibaei M, Harikumar KB, Aggarwal BB (2009) Resveratrol addiction: to die or not to die. Mol Nutr Food Res 53:115–128
Labbé A, Garand C, Cogger VC, Paquet ER, Desbiens M, Le Couteur DG (2011) Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertriglyceridemia, inflammation, and life span in a mouse model for Werner syndrome. J Gerontol A Biol Sci Med Sci 66:264–278
Chávez E, Reyes-Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Vergara P et al (2008) Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCl4 treatment in rats. J Appl Toxicol 28:35–43
Andrade JM, Paraíso AF, de Oliveira MV, Martins AM, Neto JF, Guimarães AL et al (2014) Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition 30:915–919
Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109–1122
Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675–690
Cantó C, Auwerx J (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20:98–105
Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283:20015–20026
Shen Z, Liang X, Rogers CQ, Rideout D, You M (2010) Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 298:364–374
Alberdi G, Rodriguez VM, Miranda J, Macarulla MT, Churruca I, Portillo MP (2013) Thermogenesis is involved in the body-fat lowering effects of resveratrol in rats. Food Chem 141:1530–1535
Klaunig JE (1981) Mouse liver cell cultureI. I. Hepatocyte isolation. In Vitro 17:913–925
Yin Z, Ellis EC, Nowak G (2007) Isolation of mouse hepatocytes for transplantation: a comparison between antegrade and retrograde liver perfusion. Cell Transplant 16:859–865
Murray AJ, Panagia M, Hauton D, Gibbons GF, Clarke K (2005) Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels. Diabetes 54:3496–3502
Li X, Li X, Chen H, Lei L, Liu J, Guan Y (2013) Non-esterified fatty acids activate the amp-activated protein kinase signaling pathway to regulate lipid metabolism in bovine hepatocytes. Cell Biochem Biophys 67:1157–1169
Suganami T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X, Mizuarai S (2007) Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 27:84–91
Long Y, Zierath JR (2006) AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest. 116:1776–1783
Guclu A, Erdur FM, Turkmen K (2015) The emerging role of sirtuin 1 in cellular metabolism diabetes mellitus, diabetic kidney disease and hypertension. Exp Clin Endocrinol Diabetes. doi:10.1055/s-0035-1565067
Zhang Y, Chen ML, Zhou Y, Yi L, Gao YX, Ran L (2015) Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway. Mol Nutr Food Res 59:1443–1457
Birkenfeld AL, Shulman GI (2014) Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59:713–723
Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest. 121:2111–2117
Diraison F, Moulin P, Beylot M (2003) Contribution of hepatic de novo lipogenesis and reesterification of plasma non-esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 29:478–485
Zhou LK, Xu L, Ye J, Li D, Wang WS, Li XH et al (2012) Cidea promotes hepatic steatosis by sensing dietary fatty acids. Hepatology 56:95–107
Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114:147–152
Sánchez-Fidalgo S, Cárdeno A, Villegas I, Talero E, de la Lastra CA (2010) Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol 633:78–84
Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A et al (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–342
Ahn J, Cho I, Kim S, Kwon D, Ha T (2008) Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol 49:1019–1028
Wang GL, Fu YC, Xu WC, Feng YQ, Fang SR, Zhou XH (2009) Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun. 380:644–649
Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, Shu F, Gao Y, Yuan L, Zhang Q, Mi M (2015) Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis. 47:226–232
Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A (2014) Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fattyliver disease. Nutr Res. 34(10):837–843
Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjær Poulsen M, Stødkilde-Jørgensen H, Møller HJ, Jessen N, Thorsen K, Kristina Hellberg Y, Bønløkke Pedersen S, Grønbæk H (2016) Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol 51:456–464
Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O’Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M, Coombes JS, Thomas GP, Cowin GJ, Kirkpatrick CM, Prins JB, Hickman IJ (2014) Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 12(12):2092–2103
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that there are no conflicts of interest.
Rights and permissions
About this article
Cite this article
Tian, Y., Ma, J., Wang, W. et al. Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver. Mol Cell Biochem 422, 75–84 (2016). https://doi.org/10.1007/s11010-016-2807-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-016-2807-x